Tag Archives: Rosetta Genomics

November 2017—Rosetta Genomics entered into a definitive agreement in early September to sell all of its ownership interest in PersonalizeDx to Pragmin Prognosis.

June 2015—Rosetta Genomics has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude Corp., a Fjord Ventures portfolio company. The acquisition is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.

April 2015—Rosetta Genomics has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an expectation to expand nationally over time.